Akebia Therapeutics, Inc. · NASDAQ:AKBA
Akebia Therapeutics — Corporate Update (September 2015)
10 slides from Akebia Therapeutics's corporate update, Sep 8, 2015
Slide 1: Akebia Therapeutics
Exhibit 99.2 AkebiaTherapeutics September 8, 2015
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements. Such forward-looking statements include those about Akebia's strategy, future plans and prospects, including statements regarding the potential indications, dosing and benefits of vadadustat, the development plan for v
Slide 3: Akebia at a Glance
Akebia at a Glance Akebia is a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF) Experienced Management Team with extensive knowledge in HIF biology combined with renal expertise Lead program: va
Slide 4: Top-Line Results of Phase 2 Vadadustat Study in Dialysis Patients with Anemia Related to CKD
Top-Line Results of Phase 2 Vadadustat Study in Dialysis Patients with Anemia Related to Chronic Kidney Disease
Slide 5: Vadadustat (AKB-6548) dialysis efficacy study
Vadadustat (AKB-6548) dialysis efficacy study Open Label Patient Criteria Endpoints 16 Weeks of Treatment 1st analysis: 2nd analysis: subsequent change in HGB change in HGB with dose • n= 90 at Week 8 adjustment starting at Week 8 Primary endpoint • Age: 18 –79 years old 1. Compare the change • CKD
Slide 6: Demographics
Demographics 300 mg QD 450 mg QD 450 mg TIW AllSubjects N=30 N=33 N=31 N=94 Sex-female 13 (43.3%) 15 (45.5%) 12 (38.7%) 40 (42.6%) Race White/Caucasian 24 (80.0%) 21 (63.6%) 19 (61.3%) 64 (68.1%) Black or African American 6 (20.0%) 9 (27.3%) 9 (29.0%) 24 (25.5%) Other 0 (0.0%) 3 (9.1%) 3 (9.7%) 6 (6
Slide 7: Mean HGB Average Results at Study Stages
Mean HGB Average Results at Study Stages MITTPopulation Mean Hemoglobin levels (g/dL) Baseline Week 7/8 Week 15/16 300mg Daily Dose 10.4 10.4 10.3 450mg Daily Dose 10.6 10.3 10.5 450mg Three Times-per-Week Dose10.5 10.2 10.4 PPPopulation Mean Hemoglobin levels (g/dL) Baseline Week 7/8 Week 15/16 300
Slide 8: Summary of adverse events (AEs) and serious AEs (SAEs)
Summary of adverse events (AEs) and serious AEs (SAEs) ITT Population 300 mg QD 450 mg QD 450 mg TIW All Subjects N=30 N=33 N=31 N=94 Number ofAEs 110 95 89 294 Subjects with 1 AE 26 (86.7%) 26 (78.8%) 26 (83.9%) 78 (83.0%) Subjects with 1 SAE 2 (6.7%) 6 (18.2%) 5 (16.1%) 13 (13.8%) Subjects with SA
Slide 9: Dialysis Phase 2 Study Top Line Summary
Dialysis Phase 2 Study Top Line Summary Vadadustat maintained stable HGB levels across the 3 dosing cohorts following conversion from rESA • Daily and three times-a-week regimens are viable dosing options in dialysis subjects • Hemoglobin level was maintained within the desired range while minimizin
Slide 10: Akebia Therapeutics
Akebia Therapeutics September 8, 2015
Akebia Therapeutics — Corporate Update (September 2015) on 6ix